As a leading provider of innovative technologies for the treatment of Atrial Fibrillation (Afib) and related conditions, electrophysiologists and cardiothoracic surgeons around the globe count on AtriCure to deliver best-in-class solutions that can treat even the most complex cases. The Isolator® Synergy™ Ablation System is the first medical device to receive FDA approval for the treatment of persistent Afib. The AtriClip Left Atrial Appendage Exclusion System products are the most widely used LAA management devices worldwide. The Hybrid AF™ Therapy is a minimally invasive procedure that provides a lasting solution for long-standing persistent Afib patients, and the cryoICE cryoSPHERE® probe is cleared for temporary ablation of peripheral nerves to block pain, providing pain relief in cardiac and thoracic procedures.

Primary investments are supporting innovation, clinical science, and education to focus on improving lives for patients worldwide.